Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.

Quality of care for heart patients does not improve in first year of ACO participation
Researchers tracked patient outcomes through the use of 15 performance measures related to hypertension, coronary artery disease, heart failure and atrial fibrillation.
Key takeaways from ACC.25: Advances in cardiovascular science
Former American College of Cardiology president Hadley Wilson, MD, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, explains his main takeaway messages from the ACC 2025 late-breaking trials.
Dapagliflozin improves outcomes for elderly TAVR patients with heart failure
The positive data were presented as part of a late-breaking clinical trial at ACC.25 in Chicago. One cardiologist on stage for the presentation said these findings will impact the way he manages certain TAVR patients.
Oral semaglutide reduces heart risks while helping patients move past ‘fear of the needle’
Researchers still think patients should receive an injectable version of semaglutide when possible, but new data out of ACC.25 confirm that an oral formulation of the drug is associated with significant benefits.
‘A practice-changing trial’: Semaglutide linked to key benefits for PAD patients with diabetes
Patients who present with type 2 diabetes and PAD often face substantial mobility issues. According to new data presented at ACC.25, however, treatment with semaglutide could represent a major step forward for this high-risk population.

CVS, Walgreens and Walmart ordered to pay $650M for role in opioid epidemic

Three major pharmacy names will have to fork over hundreds of millions of dollars to two Ohio counties for their roles in the opioid epidemic, a judge has ruled.

Merck Januvia Janumet Steglujan Nitroso-STG-19 (NTTP) type 2 diabetes

Possible carcinogen detected in multiple type 2 diabetes medications

To avoid a potential shortage, FDA officials have said the medications can be sold to patients on a temporary basis.

SAPT after TAVR preferred over DAPT, new meta-analysis confirms

An international team of researchers, led by specialists from Cleveland Clinic, found that DAPT was consistently linked to a greater risk of major or life-threatening bleeding events.

This latest shortage involves dobutamine, an injectable medication often prescribed for advanced heart failure and cardiogenic shock. It is also a central component of dobutamine stress echocardiography (DSE), a test used to evaluate patients with severe aortic stenosis.

A new supply issue hits cardiology: 5 recommendations for cardiologists during the dobutamine shortage

The shortage could lead to significant issues for cardiologists. The American College of Cardiology provided some words of wisdom on the ongoing issue.

Programmable RNA-DNA anticoagulant fibers may provide a better balance between blood clots and bleeding risks

“We can learn from nature, but we have built something that has never been introduced before,” one researcher said.

Autoimmune patients caught in crossfire of Supreme Court's Roe decision

Some patients with certain autoimmune diseases are finding it difficult to obtain their prescriptions for methotrexate as a result of changing abortion care laws.

“We need an answer now”: Cardiologist awarded $2.3M to study cannabis use and heart health in people living with HIV

The four-year analysis will use cardiac MRI scans to closely monitor the heart health of people living with HIV who regularly use cannabis to treat their symptoms.

Catheter-directed thrombolysis boosts survival rates for submassive pulmonary embolism

The new meta-analysis included data from nearly 10,000 patients.

Pharmaceutics

Quality of care for heart patients does not improve in first year of ACO participation

Key takeaways from ACC.25: Advances in cardiovascular science

Dapagliflozin improves outcomes for elderly TAVR patients with heart failure

Oral semaglutide reduces heart risks while helping patients move past ‘fear of the needle’

‘A practice-changing trial’: Semaglutide linked to key benefits for PAD patients with diabetes